Yes, in a limited but concrete way. A multi-gene panel that sequences APP, PSEN1, and PSEN2 can confirm whether new memory symptoms come from an inherited, near-certain cause of Alzheimer's disease, which changes the prognosis conversation and the information given to relatives — but it is not the test that decides whether a drug can be started. That decision belongs to a different gene, APOE4, which plays no role in diagnosis but determines how safely a patient can take the anti-amyloid drugs now used to treat early Alzheimer's. Separating these two tests, and what each one actually changes, is the first step to using genetic results well after a new diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the APP/PSEN1/PSEN2 panel actually finds
- Does the specific gene change what to expect?
- Why this panel doesn't forecast risk for the patient — it confirms a diagnosis
- The gene that actually changes a treatment decision: APOE4
- Putting both results together after a new diagnosis
- Frequently Asked Questions
What the APP/PSEN1/PSEN2 panel actually finds
This panel looks for a single pathogenic variant across three genes known to cause early-onset familial Alzheimer's. According to ARUP Laboratories' test information, it identifies a causative variant in roughly 60-80% of suspected familial early-onset cases, with the yield highest in people who develop symptoms at younger ages. Among the cases the panel does solve, the three genes are not equally common. PSEN1 accounts for roughly 20-70% of identified cases, APP for 10-15%, and PSEN2 for about 5%, while 20-40% of suspected familial cases remain genetically unexplained by this panel, per ARUP Laboratories.
A negative result on this panel, in other words, does not rule out a heritable cause — it only means these three specific genes aren't the explanation. A positive result is a different matter entirely. All three genes are inherited in an autosomal dominant pattern with high penetrance, meaning a single copy of the variant is enough to cause disease, and carriers face a lifetime Alzheimer's risk generally above 95%, according to a University of Washington Memory and Brain Wellness Center presentation. That makes a confirmed variant a near-certain predictor of disease in a symptomatic relative — a sharply different kind of answer than the risk-modifying gene discussed below.
Does the specific gene change what to expect?
Which of the three genes carries the variant affects the likely course of disease. PSEN1 variants are generally associated with full penetrance and roughly 10 years earlier onset and worse prognosis than PSEN2, according to Blue Cross NC's medical policy and ARUP Laboratories.
PSEN2 carriers, by contrast, are about 95% penetrant and typically develop symptoms later, in their 50s and 60s, with more frequent behavioral and psychotic features. Knowing which gene is involved can help a family anticipate the pattern of symptoms likely to follow, even though it does not change the treatment options on the table today.
Why this panel doesn't forecast risk for the patient — it confirms a diagnosis
It's worth being direct about what this testing is for once someone already has memory symptoms. Payer and laboratory policy documents state there is insufficient evidence that genetic testing for prognosis or prediction changes clinical outcomes in asymptomatic relatives, so testing a person who already has symptoms is framed mainly as diagnostic confirmation, not as a care-altering forecast for that patient, according to Grupo Triples medical policy.
That confirmation still has real value. It tells the family the cause is autosomal dominant, which means each child of an affected parent faces a 50% inheritance risk, and it opens the door to reproductive counseling for younger relatives who haven't developed symptoms. What it does not do is change which medications the patient themselves can safely take.
The gene that actually changes a treatment decision: APOE4
APOE4 is a separate, risk-modifying gene — not a diagnostic familial-Alzheimer's gene like APP, PSEN1, or PSEN2. Current payer policy still calls APOE4 testing for risk assessment in asymptomatic people investigational, according to a Blue Shield of California medical policy. But once someone is symptomatic and being considered for the anti-amyloid drug lecanemab (brand name Leqembi), APOE4 testing serves a specific, practical purpose: safety. The FDA's boxed warning and the Alzheimer's Association's appropriate-use recommendations call for APOE4 genotyping before starting lecanemab, because the drug carries a risk of ARIA — amyloid-related imaging abnormalities, a type of brain swelling or bleeding seen on MRI.
According to the FDA-approved Leqembi labeling reproduced by Drugs.com, people with two copies of the ε4 variant (about 15% of Alzheimer's patients) had ARIA of any kind in 45% of trial cases, compared with 19% in people with one copy and 13% in noncarriers. The gap widens for the more serious form. Symptomatic brain swelling (ARIA-E) occurred in about 9% of ε4 homozygotes versus 2% of heterozygotes and 1% of noncarriers, and serious ARIA was roughly 3% in homozygotes versus about 1% in the other groups, per the same Leqembi labeling. That difference is large enough to directly shape the risk-benefit conversation, and the monitoring schedule, before a patient starts the drug.
Putting both results together after a new diagnosis
For a newly symptomatic patient with a family history of early-onset Alzheimer's, the two tests answer different questions and both can matter: That last point isn't a formality. Professional guidance from the National Society of Genetic Counselors and the American College of Medical Genetics and Genomics directs that any APOE or familial-variant testing include structured pre- and post-test counseling, with a support person present for presymptomatic relatives, because results carry reproductive, insurance, and psychological implications that extend well beyond the immediate care decision, according to ARUP Laboratories' test consent documentation. A genetic counselor is the right person to sequence which test to order first and to walk the family through what each result will and won't mean.
- A positive APP/PSEN1/PSEN2 result confirms an autosomal-dominant cause, clarifies likely prognosis based on the specific gene, and informs relatives' 50% inheritance risk and reproductive counseling.
- An APOE4 result determines eligibility and monitoring intensity for anti-amyloid immunotherapy — it is a treatment-safety test, not a diagnosis, according to ARUP Laboratories and the Leqembi labeling.
- A negative familial panel does not rule out a heritable cause, since 20-40% of suspected familial cases remain unexplained by these three genes.
- Neither test should be ordered or interpreted without structured genetic counseling.
Frequently Asked Questions
If the APP/PSEN1/PSEN2 panel comes back negative, is the family history ruled out?
No. Between 20% and 40% of suspected familial early-onset cases remain unexplained by this three-gene panel, so a negative result doesn't rule out an inherited cause.
Does a positive familial variant result change which Alzheimer's drug a patient can take?
No. It confirms the cause and informs prognosis and family risk, but drug eligibility for anti-amyloid treatment is determined separately by APOE4 genotyping.
Who should order these tests?
Genetic counseling guidance calls for structured pre- and post-test counseling before either test, given the reproductive, insurance, and psychological implications of the results.
